Overview
Current Appointments & Affiliations
Professor Emeritus in Psychiatry and Behavioral Sciences
·
2022 - Present
Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences,
Psychiatry & Behavioral Sciences
Faculty Network Member of the Duke Institute for Brain Sciences
·
2008 - Present
Duke Institute for Brain Sciences,
University Institutes and Centers
Recent Publications
Structural and construct validity assessment of the schizophrenia cognition rating scale (SCoRS) using data from three international phase 3 randomized controlled trials (CONNEX programme)
Journal Article Schizophrenia Research · July 1, 2026 Cognitive impairment associated with schizophrenia (CIAS) is a fundamental symptom of the disorder, which significantly affects individuals' daily functioning and overall quality of life. Currently available antipsychotic drugs have little beneficial effec ... Full text CiteKeep your participants close, but your informants closer? The added value of high and low contact informants to supplement self-report for the cognitive impairment of schizophrenia.
Journal Article Schizophr Res Cogn · March 2026 BACKGROUND: The input of an "informant," a person in the participant's life who can evaluate levels of functioning, can supplement potentially unreliable self-reports in schizophrenia. However, this adds to the complexity of clinical trial design. To evalu ... Full text Link to item CiteAssessing the inter-rater reliability of the Schizophrenia Cognition Rating Scale: a non-interventional quantitative study
Journal Article Schizophrenia · December 1, 2025 Background: Cognitive impairment is a core feature of schizophrenia, profoundly impacting patients’ functional abilities. As such, evaluating cognition-related functional activity/impairment is essential for identifying effective treatments. This study pre ... Full text CiteRecent Grants
A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early intervention in patients with attenuated psychosis syndrom
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2017 - 2021Auditory Perception and Emotion Recognition in Young People at Risk for Psychosis
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2019Study to Evaulate the Kappa Opioid Receptor as a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluating Whether LY2456302 Engages Reward-related Neural Circuitry.
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2013 - 2017View All Grants
Education
New York University ·
1990
Ph.D.